Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in Europe and Latin America.

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

Improving Biosimilar Access Through Global Regulatory Convergence

January 15th 2025

By Skylar Jeremias

Article

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.

Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab

January 14th 2025

By Skylar Jeremias

Article

The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.

The Next Frontier: Oncology Biosimilars in 2025 and Beyond

January 13th 2025

By Prateek Yadav, MPTh, MBA

Article

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.

Streamlining Biosimilar Access: How EHR Automation Transforms Patient Care

January 12th 2025

By Skylar Jeremias

Video

Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals

January 11th 2025

By Skylar Jeremias

Article

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.

The Top 5 Biosimilar Articles for the Week of January 6

January 10th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 6, 2025.

Earlier Patent Litigation Could Accelerate US Biosimilar Market Entry

January 9th 2025

By Cameron Santoro

Article

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market entry.

Equivalence Confirmed: CT-P41 Paves the Way for Affordable Osteoporosis Care

January 8th 2025

By Skylar Jeremias

Article

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving the way for improved accessibility and cost savings in osteoporosis treatment.

BioRationality: What’s Wrong With the Indian CDSCO Biosimilar Guidelines?

January 7th 2025

By Sarfaraz K. Niazi, PhD

Article

Study Confirms CT-P42 Therapeutic Equivalence to Reference Aflibercept in DME

January 6th 2025

By Skylar Jeremias

Article

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving visual acuity in patients with diabetic macular edema (DME), with comparable efficacy, safety, pharmacokinetics, and immunogenicity at 24 weeks, with more long-term data expected.